AMORCHEM L.P. Company Profile

16:46 EDT 17th August 2018 | BioPortfolio

AmorChem ( is an early-stage, venture capital fund located in Montreal focused on creating promising life science companies from technologies originating primarily from Quebec-based universities and research centres. Launched in 2011, the AmorChem fund model combines access to financial resources with a virtual incubator structure that enables the rapid development and commercialization of its technologies. The first fund (41.2M$) has built a portfolio of 24 technologies and successfully transacted two pharma exits as well as spun-out five companies. The attractiveness of this seed fund model and the role it plays in the life science ecosystem were highlighted in September 2017 with the launch of the AmorChem II fund of 44.2M$.

News Articles [6 Associated News Articles listed on BioPortfolio]


AmorChem is pleased to announce the addition of Fondaction to the limited partners of the AmorChem II Fund L.P. The fund initially closed on September 19, 2017, having raised capi...

AmorChem Announces the Composition of Its Scientific Advisory Committee

With its second fund recently closed, AmorChem is proud to announce the composition of its scientific advisory committee. AmorChem selected these highly qualified individuals beca...

Inversago brings in $7mm via Series A

Inversago Pharma Inc. raised $7mm through its Series A financing co-led by Genesys Capital and AmorChem, which were joined by JDRF T1D Fund, Accel-Rx, Anges Québec Capital, Tarnagulla Ventures, and a...

SemaThera Announces a $2MUS Financing and a Licensing Deal for China and Japan

SemaThera Inc announces today the closing of a $2MUS co-investment from Senju Pharmaceutical Co., Ltd. and AmorChem L.P. for the development of its lead candidate, ST-102, in prep...

Senju Acquires China-Japan Rights to Diabetic Macular Edema Treatment

Senju Pharma of Osaka in-licensed China and Japan rights to a potential treatment for diabetic macular edema (DME) from Montreal's SemaThera. Senju also paired up with AmorChem L.P. to make a $2 milli...

Inversago Pharma Receives $7 Million in Series A Financing

Proceeds will support the development of new generations of cannabinoid-1 (CB1) receptor inverse agonists for the treatment of several metabolic diseases including Prader-Willi Sy...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


AmorChem ( is an early-stage, venture capital fund located in Montreal focused on creating promising life science companies from technologies originating p...


More Information about "AMORCHEM L.P." on BioPortfolio

We have published hundreds of AMORCHEM L.P. news stories on BioPortfolio along with dozens of AMORCHEM L.P. Clinical Trials and PubMed Articles about AMORCHEM L.P. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AMORCHEM L.P. Companies in our database. You can also find out about relevant AMORCHEM L.P. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Corporate Database Quicklinks

Searches Linking to this Company Record